Hunter Associates Investment Management LLC trimmed its position in Eli Lilly and Company (NYSE:LLY – Free Report) by 0.8% in ...

Shares of Eli Lilly and Company (NYSE:LLY – Get Free Report) were down 0.7% during mid-day trading on Friday after Barclays lowered their price target on the stock from $1,025.00 to $975.00. Barclays ...

Powered by its popular GLP-1 weight loss drugs, Eli Lilly's stock (NYSE: LLY) has had a strong run this year, up more than 55 ...

After both receiving FDA approval in UC, J&J and Eli Lilly are racing for their IL-23 inhibitors to get the green light in ...

Eli Lilly executives insisted that underlying demand for the medicines remained strong and that the company has enough ... wrote in an email that "destocking" — or selling existing inventory ...

While Eli Lilly has a portfolio of drugs that help address several health issues, it's the company's GLP-1 drugs ... two GLP-1 drugs that use tirzepatide as their active ingredient.

Thanks for joining us for Eli Lilly and Company's Q3 2024 earnings call ... for initiation of donanemab treatments to understand their effect on ARIA-E. In this trial, we tested a modified ...

ViaNautis Bio in Cambridge has signed a strategic collaboration agreement with Eli Lilly and Company to leverage its polyNaut® platform to develop novel products delivering genetic medicines.